2011欧洲心脏病学会关于心血管疾病干细胞治疗新进展

摘要

Stem cell transplantation therapy for ischemic cardiomyopathy remains to be the central issue in cardiovascular disease treatment in recent decade. With the accumulation of clinical data on bone marrow stem cells treatment,European Society of Cardiology ( ESC) has announced its efficacy and safety. ESC summarized the characteristics of reasonable stem cell types,cell numbers,timing and method of delivery and appropriate population. It figured out that new clinical trials were conducted on patients with chronic heart failure but not acute myocardial infarction. In addition,a new type of stem cell,induced pluripotent stem cell,was proposed to have promising future.%细胞移植治疗缺血性心肌病是近10年来心血管疾病治疗的热点.随着骨髓干细胞的临床试验数据逐步积累,欧洲心脏病学会年会公布了骨髓干细胞治疗的有效性和安全性,总结其在移植干细胞类型和数量、移植方式和时机、适合人群方面的特点,指出目前的临床研究已经从急性心肌梗死逐步转向心力衰竭患者,并提出了另一种新型诱导多能干细胞的良好远景.